Treatment of Fabry’s Disease with the Pharmacologic Chaperone MigalastatDominique P. Germain, Raphael Schiffmann, Roberto Giugliani et al.|New England Journal of Medicine|2016Cited by 555
Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension studyDominique P. Germain, Christopher Viereck, Kathy Nicholls et al.|Genetics in Medicine|2019Cited by 96